Leave Your Message
Engineered to minimize surface-induced contact pathway thrombosis, reduce shear stress, and safeguard hemodynamic stability during cardiac procedures.
Precision drainage and continuous vascular perfusion access engineered with high-grade biocompatible elastomeric latex to lower thrombotic adhesion in surgery.
View Specifications
Ultra-smooth low-shear luminal suction conduits engineered for operative fluid evacuation without inducing platelet shear activation during cardiovascular surgery.
View Specifications
Pharmaceutical-grade carrier precursors and surface modification biomaterials utilized in creating antithrombogenic covalent coatings for bypass circuits.
Explore Solutions
High-clarity, plasticizer-stabilized conduits designed for systemic anticoagulation protocols, maintaining minimal protein adsorption during prolonged CPB/ECMO runs.
Explore SolutionsBalancing profound systemic thrombosis inhibition with the mitigation of life-threatening hemorrhagic complications across global operating suites.
Cardiovascular surgery represents one of the most mechanically and biochemically demanding frontiers in modern medicine. When foreign medical devices—such as cardiopulmonary bypass (CPB) circuits, extracorporeal membrane oxygenation (ECMO) membranes, ventricular assist devices (VADs), and intravascular catheter conduits—come into direct contact with systemic blood flow, they immediately trigger the innate contact activation cascade (Factor XIIa generation) and platelet adhesion.
Historically, maintaining patency in these circuits necessitated massive doses of unfractionated heparin (UFH) monitored by Activated Clotting Time (ACT). However, severe systemic anticoagulation introduces severe clinical vulnerabilities: heparin-induced thrombocytopenia (HIT), post-perfusion bleeding diathesis, critical organ hematomas, and blood product transfusion dependency. Consequently, the global medical device industry is rapidly transitioning toward passivated, bioactive, and antithrombogenic smart biomaterials that drastically reduce systemic pharmaceutical burdens.
The global cardiovascular medical device market surpassed $58 billion in recent valuations, with anticoagulation management and surface-treated extracorporeal device sectors compounding at an annual growth rate (CAGR) of over 7.8%. Heightened procedural volumes in coronary artery bypass grafting (CABG), transcatheter aortic valve replacements (TAVR), and heart failure mechanical circulatory support drive an urgent demand for certified, hemocompatible device lines.
Eliminating the foreign-surface trigger of blood coagulation through end-point attached heparin, phosphorylcholine, and albumin-grafted membranes during prolonged circulatory bypass support.
Multi-lumen vascular access, Foley hemostatic lines, and suction drainage catheters manufactured with medical elastomers that prevent fibrin sleeve formation and microvascular occlusions.
Next-generation left ventricular assist devices (LVADs) and prosthetic heart valves engineered with titanium-carbide and pyrolytic carbon to inhibit shear-induced platelet aggregation.
Analyzing micro-level hemorheology, device surface engineering, and intraoperative fluid management.
During open-heart procedures involving cardioplegic arrest and systemic cooling, blood is continuously channeled across synthetic hollow-fiber oxygenators and reservoir tubes. Device-related anticoagulation strategies require pristine internal lumen surface finishes. High-performance triple-lumen conduits and suction tubes with precision plane or T-joints prevent cellular lysis, maintain uniform laminar flow, and prevent micro-clot deposition in surgical aspirates.
In refractory cardiogenic shock or acute respiratory failure requiring ECMO runs spanning weeks, systemic anticoagulation carries profound bleeding risks. Modern polymethylpentene (PMP) diffusion membranes combined with bioactive ionic and covalent heparin matrices resist plasma leakage and platelet exhaustion, enabling lower therapeutic ACT/aPTT targets without catastrophic oxygenator thrombosis.
Percutaneous coronary interventions (PCI), transcatheter mitral clip placements, and peripheral vascular reconstructions require guide catheters and aspiratory sheaths that do not incite vessel intimal hyperplasia or thrombus propagation. Hydrophilic polymer coatings and non-reactive elastomeric liners ensure seamless vascular tracking and high safety indices.
Cardiovascular patients on intense postoperative dual antiplatelet therapy (DAPT) and low-molecular-weight heparin (LMWH) frequently suffer mucosal bleeding. Medical safety Foley catheters with specialized pediatric and adult triple-lumen safety valves allow simultaneous continuous irrigation and drainage, mitigating urinary tract clot retention.
The technological evolution of blood-contacting medical devices revolves around three fundamental design paradigms:
Covalent bonding of synthetic nitric oxide (NO) donors and thrombomodulin analogues that actively suppress local platelet aggregation without altering systemic coagulation factors.
Super-hydrophilic poly(carboxybetaine) and sulfobetaine coatings that form a dense hydration layer, physically preventing non-specific plasma protein adsorption (fibrinogen, von Willebrand factor).
Ultra-hard, low-friction nanoscale coatings applied to metallic valves, guidewires, and mechanical pump impellers, minimizing shear stress and cellular mechanical breakdown.
Jiangxi Serum Pharma Industries Co., Ltd. delivers top-tier pharmaceutical APIs, surgical consumables, and advanced customized bio-processes globally.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Our pharmaceutical portfolio supplies critical high-purity molecules and clinical consumables to over 500 partners worldwide, powering cardiovascular care, antithrombotic therapies, and advanced surgical interventions with certified quality compliance.
Serum Pharma will continuously monitor the development of cutting-edge markets. Currently, we have partnered with industry leaders on customization across Pre-Mix, Co-Crystallization, and Bio-Fermentation.
Precision-engineered multi-ingredient formulations tailored for uniform drug release, nutritional balances, and rapid therapeutic reconstitution.
Read MoreMolecular-level crystal lattice modifications designed to enhance API bioavailability, stability, dissolution rates, and overall pharmacokinetic performance.
Read MoreHigh-yield, sustainable bio-fermentative synthesis producing ultra-pure organic intermediates, enzymes, and active pharmaceutical building blocks.
Read MoreOUR PREMIUM PRODUCTS WILL BRING BACK THE HEALTH
Our pharmaceutical products consist of biological products, vaccines, western medicines, raw material, intermediates, and medical consumables, manufactured under rigorous quality systems at accessible, cost-effective pricing.
View DetailsDERIVES FROM THE NATURE TO MAINTAIN BODY HEALTH AND BALANCE WITH PURITY
Our nutritional ingredients cover several categories including plant extracts, plant oils & proteins, probiotics, and other specialty bio-actives. We are committed to exploring health ingredients that foster long-term vitality.
View DetailsStay informed on the latest pharmacological research, market dynamics, and clinical biochemistry breakthroughs.
Comprehensive evaluation of botanical squalene extracts utilized in pharmaceutical emulsion vehicles and cellular barrier protections.
Explaining the indispensable role of corticosteroids in mitigating post-perfusion inflammatory cascade reactions during bypass.
Analysis of oral GLP-1 therapies, fast-track approvals, and their systemic vascular and metabolic outcome benefits.
Browse our integrated line of safety catheterization, aspiration conduits, bioactive intermediates, and specialized clinical ingredients.
Precision multi-channel design facilitating simultaneous bladder irrigation, drainage, and retention balloon control during anticoagulated surgical recovery.
Product Details
Cardiothoracic aspiration cannula with anti-kink walls and streamlined joint configurations to prevent turbulent hemolysis in surgical suction.
Product Details
Pharmaceutical grade precursors utilized in therapeutic formulations, cellular anti-oxidation, and vascular protective compositions.
Product Details
Refined lipid and protein matrices supporting post-operative cardiovascular patient nutrition, immune recovery, and metabolic balance.
Product Details
Specialized homogeneous blending services for active pharmaceutical ingredients, excipients, and micro-nutrient cardiovascular complexes.
Product Details
Enhancing the dissolution kinetic rate and physical stability of poorly soluble cardiovascular active molecules via co-crystal engineering.
Product Details
Microbial biotransformation platforms delivering pharmaceutical proteins, enzymes, and specialized excipient building blocks.
Product Details
Validated bacterial strains and natural active extracts targeting systemic endotoxin reduction and vascular wall integrity maintenance.
Product Details